Skip to main content
Emergent BioSolutions Inc. logo

Emergent BioSolutions Inc. — Investor Relations & Filings

Ticker · EBS ISIN · US29089Q1058 LEI · 549300YW6TUOX8BE5103 US Manufacturing
Open in API
Filings indexed 1,264 across all filing types
Latest filing 2010-08-24 Merger & Acquisition
Country US United States of America
Listing US EBS

About Emergent BioSolutions Inc.

https://emergentbiosolutions.com/

Emergent BioSolutions Inc. is a life sciences company specializing in solutions for public health threats. The company develops, manufactures, and delivers medical countermeasures for national security and public health preparedness, addressing threats such as anthrax, smallpox, botulism, and Ebola. In addition to its biodefense portfolio, Emergent provides commercial products for endemic health crises, notably the opioid epidemic. The company also offers contract development and manufacturing services through strategic partnerships, leveraging its specialized capabilities to support biopharmaceutical innovators, governments, and non-governmental organizations.

Recent filings

Filing Released Lang Actions
425 Filing
Merger & Acquisition Classification · 95% confidence The document is a filing pursuant to Rule 425 under the Securities Act of 1933 and Rule 14a-12 under the Securities Exchange Act of 1934, which are typically used for merger communications. The text discusses the proposed acquisition (merger) of Trubion Pharmaceuticals by Emergent BioSolutions, including forward-looking statements, details about the merger, and references to proxy statements and registration statements to be filed. It also includes detailed strategic and operational information about the companies involved and the merger rationale. The presence of Rule 425 and Rule 14a-12 filings, the focus on the merger transaction, and the detailed merger-related disclosures indicate this is a merger communication filing. Therefore, the document should be classified under Merger & Acquisition (MA). The document length (13,088 characters) and content confirm it is the actual communication, not just an announcement or a proxy statement. Confidence is high due to the clear regulatory references and content focus.
2010-08-24 English
SC 13D Filing
Major Shareholding Notification
2010-08-23 English
8-K Filing
M&A Activity Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by Emergent BioSolutions Inc. dated August 12, 2010. It discusses a proposed merger with Trubion Pharmaceuticals, including references to filings such as Form S-4 registration statement and proxy statements related to the merger. The document includes a presentation as an exhibit. The content focuses on merger-related communications and solicitation of proxies, which aligns with merger announcements and related materials. The document is not a full merger proxy statement or tender offer filing itself but a current report announcing merger-related events and communications. Therefore, the most appropriate classification is 'M&A Activity' (TAR), which covers announcements and documents related to merger proposals or takeover bids.
2010-08-19 English
425 Filing
M&A Activity Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by Emergent BioSolutions Inc. dated August 12, 2010. It discusses a proposed merger with Trubion Pharmaceuticals, Inc. and references filings such as a registration statement on Form S-4 and proxy statements related to the merger. The document includes a section titled 'Additional Information and Where to Find It' and 'Participants in Solicitation,' which are typical in merger-related communications. The document also mentions a presentation as an exhibit. The content is focused on merger-related announcements and solicitation materials rather than the merger proxy statement itself or the merger completion. Given the references to Rule 425 communications and solicitation materials, this document is best classified under M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids. The document length (5112 characters) and content indicate it is not a full proxy statement or registration statement but a current report announcing and providing information about the merger process.
2010-08-19 English
8-K Filing
M&A Activity Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 18, 2010, by Emergent BioSolutions Inc. It discusses a proposed merger with Trubion Pharmaceuticals, including references to filings such as a registration statement on Form S-4 and proxy statements related to the merger. The content includes solicitation materials, information about the merger process, and communications to employees about the merger. There are no financial statements or detailed financial performance data presented. The document is primarily an announcement and communication regarding merger activity and solicitation of proxies. Therefore, it fits best under the category related to merger announcements and related communications. The appropriate classification is M&A Activity (Code: TAR).
2010-08-18 English
425 Filing
Merger & Acquisition Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 18, 2010, by Emergent BioSolutions Inc. It discusses a proposed merger with Trubion Pharmaceuticals, including references to filings such as Form S-4 and proxy statements related to the merger. The text includes solicitation material and communications pursuant to Rule 425 and Rule 14a-12, which are related to merger communications and proxy solicitations. The document contains no financial statements or detailed financial analysis but focuses on merger-related announcements and communications to employees and shareholders. Therefore, this filing is best classified under Merger & Acquisition (MA), which covers merger, acquisition, and tender-offer filings such as Form 425 and merger communications.
2010-08-18 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.